In this retrospective observational study performed in a high-volume hepatobiliary-pancreatic unit, we evaluated the effect of a surgery-specific goal-directed therapy (GDT) physiologic algorithm on complications and length of hospital stay. We compared patients who underwent pancreaticoduodenectomy with either a standardised Enhanced Recovery After Surgery program (usual care group), or a standardised Enhanced Recovery After Surgery program in combination with a surgeryspecific cardiac output-guided algorithm (GDT group). We included 145 consecutive patients: 47 in the GDT group and 98 in the usual care group. Multivariable associations between GDT and lengths of stay and complications were investigated using negative binomial regression. Postoperative complications were common and occurred at similar frequencies amongst the GDT and usual care groups: 64% versus 68% respectively, P=0.71; odds ratio 0.82; (95% confidence interval 0.39-1.70). There were fewer cardiorespiratory complications in the GDT group. Median (interquartile range) length of hospital stay was ten days (8.0-14.0) in the GDT group compared to 13 days (8.8-21.3) in the usual care group, P=0.01. Median (interquartile range) total intraoperative fluid was 3,000 ml (2,050-4,175) in the GDT group compared to 4,500 ml (3, 325) in the usual care group, P <0.0001; but by day one, the median (interquartile range) fluid balance was similar (1,198 ml [700-1,729] in the GDT group versus 977 ml [419-2,044] in the usual care group, P=0.96). Use of vasoactive medications was higher in the GDT group. In our patients undergoing pancreaticoduodenectomy, GDT was associated with restrictive intraoperative fluid intervention, fewer cardiorespiratory complications and a shorter hospital length of stay compared to usual care. However, we could not exclude an influence of surgical caseload, which we have previously found to be an important variable. We also could not relate the increased hospital length of stay to cardiorespiratory complications in individual patients. Therefore, these observational retrospective findings would require confirmation in a prospective randomised study.
Pancreatic cancer is one of the most common causes of cancer death worldwide. The standard treatment for resectable malignant or benign cancers arising in the pancreatic head, ampulla, distal bile duct or duodenum is pancreaticoduodenectomy (PD). This complex, highly invasive procedure is performed most commonly in elderly patients, and is associated with significant perioperative morbidity. The role of intraoperative intravenous (IV) fluids is addressed by multiple reviews. However, no consensus has been established, largely due to a significant heterogeneity of small clinical trials 1, 2 . A 2011 meta-analysis looking at the role of goal-directed vasoactive medication and IV fluids in high-risk surgical patients outcomes identified a reduction in both morbidity and mortality 3 . Recently, however, in the largest goal-directed therapy (GDT) trial to date-the OPTIMISE trial (Optimisation of Cardiovascular Management to Improve Surgical Outcome), the use of GDT in patients undergoing major gastrointestinal surgery did not decrease complications or 30-day mortality 4 . Of note, the authors reported that GDT was associated with a reduction in the composite primary outcome for patients undergoing small bowel surgery with or without pancreas surgery. Subgroup analysis did not report how many patients underwent PD, or whether there was a significant clinical benefit for GDT in this group of patients.
Enhanced Recovery After Surgery programs (ERAS) for PD can be effectively implemented without compromising patient safety or increasing length of hospital stay [5] [6] [7] [8] [9] . However, there are no studies that have evaluated the impact of a surgery-specific cardiac output-guided algorithm on perioperative fluid use and requirements for inotropic or vasopressor medications in patients undergoing PD in a high-volume pancreatic surgery centre. In addition, the use of GDT in preventing postoperative complications and improving length of hospital stay in this setting is also unclear. Previously, in a retrospective review of 150 patients undergoing PD in our hospital between 2006 and 2012, we reported that restrictive perioperative fluid intervention, negative cumulative fluid balance and higher surgeon caseload were associated with fewer complications and shorter lengths of hospital stay 10 . We did not evaluate whether ERAS impacted on fluid intervention, and neither did we evaluate whether advanced haemodynamic monitoring was used. The impact of ERAS and advanced haemodynamic monitoring on perioperative outcomes was not evaluated. ERAS for major hepatobiliary or pancreatic surgery was introduced in our institution in August 2009 and by 2010 was established as standard care. Advanced haemodynamic monitoring was not used routinely as a part of ERAS despite a surgery-specific cardiac output-guided algorithm ( Figure  1 ) being developed to further standardise intraoperative anaesthesia management. In view of these unanswered questions, we performed a retrospective observational study comparing the development of perioperative complications and length of hospital stay in patients who underwent PD with either a standardised ERAS program, or a standardised ERAS program in combination with a surgery-specific cardiac output-guided algorithm.
Methods
Austin Hospital is a university hospital with expertise in hepatobiliary-pancreatic surgery, including liver transplantation. Between January 2010 and September 2015, data for this study was extracted for all patients who underwent PD from a prospectively managed electronic hospital database. Outcome data from 85 patients were extracted from a previous retrospective study 10 . The Austin Health Human Research Ethics Committee approved the study (HREC no: LNR/2015/Austin/321). Inclusion criteria included adult patients (age >18 years) undergoing open PD with a standard ERAS protocol. Patients undergoing total, distal or completion pancreatectomy were excluded. Patients were retrospectively classified into one of the two treatment groups: usual care group, which included patients who underwent PD with standard ERAS protocols, or GDT group, which consisted of patients managed by standard ERAS in addition to a surgery-specific cardiac output-guided algorithm. The use of advanced haemodynamic monitoring was at the discretion of the attending anaesthetist.
Prior to ERAS implementation the perioperative management of patients undergoing PD differed in several ways compared to current ERAS management: i) Preoperative and postoperative management was not multidisciplinary. ii) There was no dedicated preoperative haemoglobin optimisation program. iii) Patients were routinely fasted from midnight prior to surgery. iv) There was wide variation in intraoperative and postoperative fluid intervention practice. v) All patients were kept "nil per mouth" postoperatively for variable lengths of time. vi) There was no policy for removal of nasogastric tubes. vii) There was no policy for removal of urinary catheters. viii) Physiotherapy was not mandated twice daily. ix) Postoperative daily weights of patients were not recorded. x) De-escalation fluid therapy was not practised.
Current standardised ERAS (usual care group)
All patients in this study underwent preoperative multidisciplinary assessment. A thorough evaluation of the patient's cardiorespiratory status was performed. Routine biochemical and haematological tests were evaluated and, where necessary, optimised prior to surgery. All patients underwent preoperative haemoglobin optimisation based on the National Blood Authority of Australia's patient blood management initiative 11 . Standard perioperative care included strict transfusion practice in accordance with these guidelines. Postoperatively, all patients were admitted to the intensive care unit (ICU) for at least one overnight stay, and then discharged to a dedicated hepatobiliary surgical ward under a multidisciplinary team of anaesthetist, surgeon, perioperative physician and pain clinician.
General anaesthesia was managed using an ERAS protocol designed to standardise care. In brief, all patients were fasted for six hours for solids and two hours for clear fluids. All patients, unless contraindicated, were offered epidural or intrathecal morphine analgesia, which was individualised for each patient at the discretion of the attending anaesthetist. For patients receiving intrathecal analgesia, morphine (300 to 400 µg) was inserted at a lumbar spinal level prior to induction of anaesthesia. Patients receiving epidural analgesia had a low thoracic epidural catheter inserted at T8/9 or T9/10 spinal level. All patients received intraoperative antibiotic prophylaxis. Patients did not receive any IV fluid loading prior to induction of anaesthesia. Induction of anaesthesia consisted of a balanced technique using propofol (1 to 3 mg/kg IV), fentanyl (1 to 3 ug/kg IV) and a non-depolarising neuromuscular blocker. Antiemetic prophylaxis consisted of dexamethasone (8 mg IV), and thromboprophylaxis included enoxaparin (40 mg subcutaneously).
Routine intraoperative monitoring included continuous electrocardiography, pulse oximetry, capnography, central venous pressure, invasive blood pressure, urine output and core body temperature. Intraoperatively, fluid intervention and use of vasoactive drugs was at the discretion of the attending anaesthetist. Maintenance of anaesthesia was achieved using sevoflurane or desflurane in 50% oxygen:50% air titrated to a bispectral index of 40 to 60. For patients not receiving epidural anaesthesia, intraoperative analgesia consisted of a short-acting IV opioid infusion (remifentanil 0.1 to 0.3 ug/kg/minute) discontinued prior to surgical closure of the wound. Patients then received IV fentanyl (20 ug/ml bolus, five minute lockout) or morphine (1 mg bolus, five minute lockout) patient-controlled analgesia until oral intake resumed, after which they received oral oxycodone (10 to 20 mg every four hours). For patients receiving epidural analgesia, intraoperative analgesia consisted of 6 ml boluses of epidural bupivacaine 0.25% repeated intraoperatively when clinically indicated, and postoperative analgesia consisted of an epidural infusion of ropivacaine 0.2% in combination with fentanyl 2 µg/ml at eight to 12 ml/hour, continued postoperatively for 72 hours.
Postoperative analgesia was optimised by an acute pain service that reviewed all patients twice daily. Patients received strict paracetamol (1 g IV) every six hours for 48 hours. Where there was no contraindication, rescue analgesia consisted of non-steroidal anti-inflammatory drugs (ketorolac 30 mg IV eight hourly), tramadol (50 to 100 mg IV six hourly) or ketamine (0.1 to 0.2 mg/kg/hour IV). Postoperatively all patients received physiotherapy twice daily and prophylactic antibiotics for 24 hours. Clear fluids were encouraged immediately postoperatively as tolerated. In addition, all patients received maintenance fluids at 84 ml/hour with additional 250 ml fluid challenges (balanced crystalloid or 4% albumin) used at the discretion of the attending clinician. On the first postoperative day, the nasogastric tube was removed if drainage was less than 300 ml for six consecutive hours. A soft diet was encouraged in the absence of nausea or vomiting, after which pancreatic enzyme supplements were initiated.
Surgical drains were removed when there was no evidence of any pancreatic or biliary leakage. Indwelling urinary catheters were removed within 72 hours postoperatively. Frusemide (10 to 20 mg IV or orally) was prescribed if daily 24-hour fluid balances were greater than 1,000 ml, or for postoperative weight gain of greater than 1 kg. Maintenance IV fluid therapy was reduced after 24 hours postoperatively once oral intake was tolerated. Other routine postoperative medications included a proton pump inhibitor for gastric protection and laxatives to achieve regular bowel motions. Discharge criteria included unassisted mobilisation, full dietary intake, satisfactory pain control, and no evidence of a medical or surgical complication.
Goal-directed therapy group
The decision whether to use GDT was entirely at the discretion of the attending anaesthetist. Patients in the GDT group received the same ERAS protocol described above, in addition to intraoperative use of an advanced haemodynamic monitoring device (FloTrac® System 4.0, Edwards Lifesciences, Irvine, CA, USA). The FloTrac sensor was used with the EV1000 clinical platform to continuously measure and display key flow parameters, which included cardiac output, stroke volume and systemic vascular resistance. IV fluid and vasoactive drugs were administered consistent with the surgery-specific algorithm, previously reported by our group 12 and outlined in Figure 1 . We used a stroke volume variation (SVV) of >20% as a target for fluid intervention.
Data collection
Austin Health utilises Cerner®, an electronic medical record that allows comprehensive electronic data capture and access to patient health information in the perioperative setting. Anaesthesia records were entered manually by the attending anaesthetists. Detailed preoperative, intraoperative and postoperative patient data was entered into the electronic database and crosschecked by three independent researchers. Patient characteristics including body mass index, American Society of Anesthesiologists physical status, comorbidities and preoperative laboratory tests were recorded. Operative details included anaesthetic technique, intraoperative fluid administration, fluid balance and use of vasoactive medications. Detailed fluid intervention and postoperative fluid balance were collected on postoperative day one. Fluid balances were calculated by subtracting total output (urine output, blood loss, loss from drains, vomitus) from total input (all IV fluid intervention, parenteral medications, feeding, oral water intake). Third space losses were not included, as they were considered negligible. Electronic haemodynamic data from the FloTrac device were also recorded.
We used this information to compare length of hospital stay and the development of complications in patients who underwent PD with either a standardised ERAS program (usual care group), or a standardised ERAS program in combination with a surgery-specific cardiac output-guided algorithm (GDT group). Length of stay was defined as the time from surgical wound closure until the patient was formally discharged from the acute hospital ward. All complications were graded according to the Clavien-Dindo classification 13 . Pancreatic leak and delayed gastric emptying were classified according to the International Study Group of Pancreatic Surgery [14] [15] [16] . Non-cardiogenic pulmonary oedema was defined as radiographic evidence of alveolar fluid accumulation with no clinical evidence of cardiac aetiology. All other complications were defined and classified according to the European Perioperative Clinical Outcome definitions 17 . Baseline characteristics and intraoperative variables, duration of surgery, and the amount and type of IV fluid administered were also collected.
Statistical analysis
Continuous data was tested for normality and measures of central tendency compared as means (standard deviations, SD) using the Student's t-test for normally distributed variables and as medians (interquartile range, IQR) using the Mann-Whitney U test, unless otherwise stated. Multivariable associations between GDT and length of stay were investigated using negative binomial regression with length of stay treated as the count of days with corresponding effect size reported as incidence rate ratio (IRR) with 95% confidence intervals (CI). IRR indicates a factor change in expected length of stay compared to the reference group, e.g. IRR=2 means that the expected length of stay is twice as long as that of the reference group. The association between GDT and number of complications was investigated in the same way. A two-tailed P-value <0.05 was considered as statistically significant for both these outcomes. In addition, multivariable associations between GDT and absence or presence of individual complications were investigated using logistic regression modelling with corresponding effects reported as odds ratios (ORs) and 95% CIs. The association between GDT and the use of vasoactive drugs was investigated using two types of regression models: a logistic regression for an individual drug being used or not, and linear regression with robust standard error estimation for the amount of drug administered. Finally, the association between GDT and the amount of fluid used was investigated using linear regression with robust standard error estimation, with corresponding effects reported as the difference in means with 95% CI. All the models were adjusted for the following set of a priori chosen covariates: preoperative albumin, length of surgery time, and epidural anaesthesia. Albumin was chosen as a marker of nutritional status, duration of surgery as a marker of surgical complexity, and epidural anaesthesia as a marker for larger requirements for perioperative fluid intervention. In order to preserve Type I error at 0.05 for investigating IV fluid and vasoactive drug outcomes where multiple individual comparisons were being made, a multiplicity-corrected P-value of less than 0.01 was considered as statistically significant for individual comparisons. Statistical analysis was performed using commercial statistical software STATA/IC v.13. Figures were constructed using Prism 6.0 GraphPad software (La Jolla, CA, USA). We included the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement checklist of items for observational studies to report our findings 18 .
Results
One hundred and forty-five consecutive patients undergoing PD were evaluated; 47 in the GDT group and 98 in the usual care group. The median (IQR) age in the GDT group was 66 years (58-75), and 66 years (54-73) in the usual care group; P=0. 42 . No statistically significant differences between the groups in gender, body mass index, American Society of Anesthesiologists physical status or comorbidities were observed (Table 1) . Preoperative median (IQR) albumin was higher in the GDT group 39 g/l (32-44) compared with the usual care group 35 g/l (31-39), P=0.003.
Length of stay and complications
The median (IQR) and mean (SD) length of hospital stay for all patients were 12 (8.0-17) and 16 (16.1) days respectively. Median (IQR) and mean (SD) length of hospital stay were 10 (8-14.0) and 12 days (8.4) in the GDT group compared to 13 (8.8-21. 3) and 18 days in the usual care group (P=0.01 and 0.009 respectively). From 2010 to 2014, the median (IQR) length of hospital stay in the usual care group was 15 (10-23) days, 12 (8-21) days, 13 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) days, and 16 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) days, respectively. From 2011 to 2015, the median (IQR) length of hospital stay in the GDT group was 8 (7-9) days, 8.5 (7-10) days, 13 (10-15) days, and 9 (7-15) days, respectively.
After adjusting for preoperative albumin, duration of surgery, and epidural use, GDT group expected length of hospital stay remained approximately 30% shorter than that for the usual care group, IRR 0.72 (95% CI 0.55-0.94) P=0.017. Details of postoperative complications are summarised in Table 2 (on next page). Postoperative complications were common and occurred at similar frequencies amongst the GDT and usual care groups: 64% versus 68%, P=0.71; OR 0.82 (0.39-1.70), respectively. The total number of complications was less in the GDT group compared with usual care; 77 versus 209, P=0.04, IRR 0.62 (0.40-0.94). The majority of complications were graded as Clavien-Dindo Class 1 and 2. Cardiogenic pulmonary oedema occurred in no patients in the GDT group compared to 12 patients (12%) in the usual care group; P=0.0087, OR 0.07 (0.00-1.26). One patient (2%) in the GDT group developed pulmonary atelectasis versus 13 patients (13%) in the usual care group; P=0.035, OR 0.14 (0.02-1.06). The rest of the complications were similar between the groups. No significant differences were observed between the groups in return to theatre (P=0.73) or mortality within 30 postoperative days (P=0.99).
Fluid use and vasoactive drugs
Details of intraoperative variables including fluid intervention and use of vasoactive medications are summarised in (on next page). A summary of the haemodynamic variables recorded from the FloTrac device are presented in Figure 2 (next page). The median (IQR) and mean (SD) intraoperative amount of crystalloids administered were lower in the GDT group compared to the usual care group: 2,200 ml (2,000-4,000), 2,703 ml (1,347) versus 4,000 ml (3,000-5,000), 4,065 ml (1,926); P <0.0001, effect size -1,335 (-1,910--800). Median (IQR) and mean (SD) total intraoperative fluid were 3,000 (2,050-4,175) and 3,061 ml (1, 360) in the GDT group compared to 4,500 ml (3, 325 ) and 4,706 ml (2, 265) in the usual care group, P <0.0001; effect size -1747 (-2,372--1,121). Similarly, median (IQR) and mean (SD) fluid balances were lower in the GDT group; 2,200 ml (1,005-3,300), and 2,289 ml (1,558) versus 3,632 ml (2,380-4,685), and 3,827 ml (2,062) in the usual care group, P <0.0001. Epidural anaesthesia was employed in 12 (26%) participants in the GDT group and 34 (35%) participants in the usual care group. Intrathecal analgesia was used in 30 (31%) participants in the GDT group and 25 (53%) participants in the usual care group. The median (IQR) total intraoperative fluid used in patients with epidural anaesthesia was 4,500 ml (3,750-5,300), compared to patients without epidurals 3,500 ml (2,450-5,000), P=0.01. With adjustment for covariates, intraoperative fluid balance remained significantly less in the GDT group, P <0.0001; effect size -1,647 ml (-2,347--946). Postoperatively the median (IQR) fluid balance on postoperative day 1 was 1,198 ml (700-1,729) in the GDT group compared to 977 ml (419-2,044) in the usual care group, P=0.96; effect size -191 ml (-573-189).
Eighteen patients (38%) in the GDT group received metaraminol versus 73 patients (74%) in the usual care group, P=0.002, OR 0.25 (0.10-0.61). However, overall 
Discussion
We evaluated the effect of GDT on length of hospital stay and complications in patients undergoing PD who received ERAS alone or ERAS in combination with a surgery-specific cardiac output-guided haemodynamic algorithm. Length of hospital stay was shorter in the GDT group. Whilst length of hospital stay was lower in the GDT group, we cannot comment whether this was related to restrictive fluid therapy, or to fewer surgical complications, completely unrelated to the physiologic surgery-specific cardiac outputguided algorithm used. Although there were no significant differences in the number of patients with complications between the groups, there were more complications per patient and a higher incidence of cardiogenic pulmonary oedema and pulmonary atelectasis in the usual care group. In the GDT group, fluid therapy was more restrictive intraoperatively, and use of vasoactive medications was much higher, but by day one fluid balance was similar. We also could not exclude an influence of surgical caseload, which we have previously found to be an important variable affecting both complications and length of stay in PD patients. Therefore, these retrospective findings, which suggest that for patients undergoing PD, length of stay and the incidence of cardiorespiratory complications may be improved using a physiologic surgery-specific GDT algorithm, would require confirmation in a randomised prospective study.
Despite efforts to reduce morbidity in our centre with the implementation of ERAS protocols, our morbidity rate was still in excess of 60%, whether or not GDT was utilised. The baseline characteristics of patients in this study are consistent with other studies of patients undergoing this procedure 19, 20 and complications were similar to those reported in other high-volume tertiary centres 21, 22 . These findings indicate that if GDT has a benefit, it is primarily related to the volume of fluid infused intraoperatively, and how and when vasoactive medications are used, as opposed to perioperative fluid and pressor use. In our institution fast-track protocols have reduced length of stay in patients undergoing uncomplicated PD 23 .
Almost twice as much fluid was administered intraoperatively in the usual care group compared to the GDT group. Given these findings, it is therefore plausible that the liberal fluid therapy was independently associated with a higher incidence of cardiopulmonary complications. On the other hand, the fluid balance on day one was similar between groups, as was the ICU length of stay. Other studies have demonstrated a strong association between liberal fluid administration and impaired pulmonary, cardiac, gastrointestinal and renal function, and increased postoperative complications and prolonged recovery 10,24-28 . Further, retrospective outcome data recently performed in our institution, which specifically evaluated the impact of fluid intervention in patients undergoing PD, confirm a strong association between liberal perioperative fluid use and positive fluid balance, and the development of complications 10 . In contrast, in the current study, the day one fluid balance was similar between groups. Previously we also found that there was an important association between surgical caseload and both complications and length of stay in PD patients, but we could not examine this variable in the current study.
ERAS guidelines recommend a near zero fluid balance and our findings underline a significant non-compliance with current ERAS fluid guidelines. Fluid practices in the usual care group in this study contradicted several clinical guidelines, ERAS recommendations and reviews, which reinforce the benefits of a restrictive or even cumulative fluid balance approach to fluid therapy 7, 27, [29] [30] [31] . Adherence to ERAS guidelines is currently not audited in our institution, and stringent compliance with such guidelines may have resulted in less variation in fluid intervention practices, and no differences in outcomes. Previous fluid intervention data from our institution 20 showed that in patients who underwent major abdominal surgery, mean intraoperative fluid use was 6,305 ml, and for the subgroup of patients undergoing upper gastrointestinal surgery, mean intraoperative fluid use was 7,464 ml. Therefore, whilst variation in fluid practice may still be pervasive, ERAS has significantly reduced this variation, and the addition of GDT using a physiologic surgery-specific cardiac output-guided haemodynamic algorithm has reduced this variation even further. Nevertheless, the non-compliance with ERAS guidelines for some patients must be considered when interpreting the findings of this study.
The beneficial role of ERAS after pancreatic surgery has been reflected in a recent systematic review 5, 7 , and has led to the implementation of specific ERAS guidelines 7 . Of note, however, there have been inconsistent findings when assessing the optimal intraoperative fluid regimen 19, [32] [33] [34] . As such, currently there is no unanimous formulation for the most effective fluid management strategy for patients undergoing PD. The complexity and individual variability of human physiology, together with pre-surgical morbidities, advanced age, and the impact of the prolonged and highly invasive surgery, reinforces why a one-size-fits-all approach to fluid therapy for PD is not feasible 35, 36 . Our findings indicate that GDT in combination with an ERAS program was associated with a more restrictive fluid balance regimen in our institution. Our findings support the subgroup analysis reported in the OPTIMISE Trial, where GDT was associated with a clinical benefit for patients undergoing small bowel surgery with or without pancreatic surgery 4 . This is despite the OPTIMISE Trial reporting no overall benefit when including all major gastrointestinal surgical patients 4 . Our findings are also consistent with the updated meta-analysis maintaining that GDT leads to a reduction in length of hospital stay and reduction in rate of complications 4 .
There are several strengths and limitations of this study. Only 145 records were reviewed, of which 47 patients underwent PD using a surgery-specific cardiac output-guided algorithm. To date, however, this is the largest series of detailed fluid intervention data combined with the use of a physiologic GDT algorithm in patients undergoing PD. All haemodynamic variables measured from the FloTrac device were assessed invasively, stored electronically on the device, and not amenable to ascertainment bias or derivation. However, the documentation of haemodynamic data by the anaesthetists on the anaesthesia records was inconsistent, e.g. less than 15% of anaesthetists documented mean arterial pressure, therefore accurate comparisons between the groups for haemodynamic data were not possible.
The cardiac output algorithm we used is specific to patients undergoing PD. It should be noted that arterial waveform was utilised to measure SVV, rather than transoesophageal echocardiography. There is conflicting evidence regarding the accuracy of FloTrac SVV representing fluid responsiveness. SVV analysis using the FloTrac system has reliably been shown to be a predictor of patient fluid responsiveness 37, 38 . SVV measured using FloTrac and Doppler has been shown to have similar performance in predicting fluid responsiveness in liver transplant patients 39 . Two recent studies, however, found FloTrac SVV to have an area under the receiver operating characteristic curve of just 0.51 and 0.57 respectively when comparing with oesophageal Doppler monitors 40, 41 . In addition, SVV may be inconclusive between 9% and 13% in approximately 25% of patients during general anaesthesia 40, 41 . Therefore, in contrast to conventional recommendations 39 , we considered a SVV of 20% as a conclusive and a clear cutoff for effective volume expansion from fluid intervention. We cannot, however, extrapolate our surgery-specific cardiac output-guided algorithm to other types of complex surgery, other scheduled (or emergency) types of operations, or to older, sicker, or morbidly obese patients. Arterial waveform analysis can be performed using only an arterial line and therefore has the greatest potential for translation into routine clinical practice. There are limitations to this technique; notably, the patient must have a regular heart rhythm and be mechanically ventilated with a standard tidal volume 42 . As such arterial waveform analysis is well suited to, but limited to, the operating room and intensive care units.
The focus of this study was to explore the association of a surgery-specific cardiac output-guided algorithm on patient outcomes. We used statistical analysis to adjust for important confounders that frequently impact on fluid intervention and postoperative outcomes, but were not able to include surgical caseload, an important variable in a previous study 10 . Whilst all anaesthetists involved in hepatobiliary-pancreatic surgery in our institution use GDT to a similar extent, our findings may be subject to bias from both clinician selection (certain anaesthetists selecting to use GDT), and patient selection (selective use of GDT in certain patients). We acknowledge that we cannot control for this potential bias and confounder; however, all anaesthetists caring for patients in this study were proficient in the use of advanced haemodynamic monitoring devices and GDT. As more GDT versus usual care surgery was done in the later years, we did not introduce year as an adjustment covariate in the model due to excessive collinearity. We appreciate that there is therefore a potential for confounding between the effect of intervention and years that cannot be resolved within the frame of a retrospective study and we appreciate this is a limitation.
We acknowledge there is no absolute consistency amongst anaesthetists for fluid intervention, with regard to the amount and type of fluid administered, or to the choice and use of vasoactive medication. Further prospective randomised controlled trials would be required to avoid this potential bias. As all our hepatobiliary surgeons and anaesthetists are part of a dedicated service, we did not collect outcomes of individual anaesthetists or surgeons. Looking at individual surgeon outcomes is complex for several reasons. All our hepatobiliary-pancreatic surgeons can be considered high-volume surgeons; however certain surgeons undertake more complex resections, often involving extensive vascular reconstruction. Looking at individual surgeons without adjusting for complexity of surgery is difficult. Defining surgical complexity is challenging with no established metrics to accurately score this. Second, in our centre, for most complex resections there are often two consultant surgeons present, although the admission will fall under a single surgeon. In addition, low-volume surgeons (less than eight resections/year) often work with high-volume surgeons, again complicating analyses if only outcomes for individual surgeons are assessed. Finally, taking into consideration involvement by the surgical advanced trainee and the anaesthetist also confounds outcomes. We acknowledge there may be individual variation in practice between clinicians affecting outcomes; however during the study period there were no major changes to the ERAS program in the form of training workshops, use of GDT protocols, or changes to ERAS or postoperative care practice. There were also no changes to anaesthesia or surgical staffing; however increases in skill base or cases completed may have impacted on improvement in length of stay. These inherent confounders are difficult to quantify. This is a single-centre study, performed in a high-volume centre for pancreatic surgery, which limits the external validity of our findings to other institutions.
All postoperative complications were extracted from Cerner, an online medical record program used at the Austin Hospital. Postoperative complications were recorded and coded on the patient's discharge summary that was then reviewed. There is no observational bias due to the objective nature of postoperative complications coding. As patients had the same management postoperatively, the mechanism by which a ~1.7 litre difference in intraoperative fluids alone could have affected readiness for discharge is unclear. This may be a consequence of a higher incidence of cardiopulmonary complications observed and prolonged medical management. Our findings are hypothesis-generating and may provide valuable data for power calculations for future prospective GDT interventional trials in the setting of PD. Finally, as the study design is retrospective, we cannot establish a causal relationship between the surgery-specific cardiac output-guided haemodynamic algorithm and improved outcomes. From our findings, any randomised controlled trial of GDT versus usual care would have to recruit several thousand patients to reliably detect or exclude a clinically important difference in surgical complications between groups.
Conclusion
In conclusion, use of GDT was associated with less fluid use intraoperatively, but more vasopressor use, including noradrenaline and dopamine. No statistically significant differences in twenty-four hour fluid balance or ICU length of stay were identified. There were no significant differences in the number of patients with complications; however, there were more complications per patient in the usual care group. We are unable to relate the cause of the increased length of stay to the specific types of complications, i.e. medical versus surgical. Whilst our retrospective findings suggest that the use of a specific intraoperative cardiac output-guided haemodynamic algorithm was associated with a reduction in cardiorespiratory complications and shorter length of hospital stay, we could not exclude an effect of other potentially important variables. Therefore, further randomised prospective studies would be required to confirm whether this is a real and reproducible effect.
